Document 0354
 DOCN  M94A0354
 TI    Neutralization of HIV-1 [see comments]
 DT    9412
 AU    Golding H; D'Souza MP; Bradac J; Mathieson B; Fast P; Laboratory of
       Retrovirus Research, FDA/CBER, Bethesda, Maryland; 20892.
 SO    AIDS Res Hum Retroviruses. 1994 Jun;10(6):633-43. Unique Identifier :
       AIDSLINE MED/94355107
 CM    Comment in: AIDS Res Hum Retroviruses 1994 Jun;10(6):631-2
 AB    A Workshop on Neutralization of HIV-1: Technology and reagents for
       analysis of prophylactic vaccines clinical trials, sponsored by the Food
       and Drug Administration (FDA) and the Division of AIDS, National
       Institute of Allergy and Infectious Diseases (NIAID), National
       Institutes of Health (NIH), was held on April 19-20, 1993, in Bethesda,
       Maryland. This workshop brought together researchers who are involved in
       the development, testing, and evaluation of HIV-1 prophylactic vaccines.
       The major objectives were (1) to discuss critically the different
       neutralization and binding assays that are currently used in the
       evaluation of immune sera; (2) to identify assays that will measure the
       most relevant antibodies, which are likely to predict neutralization of
       primary isolates; and (3) to identify well-characterized reference
       reagents, which could be used to standardize neutralization assays used
       in laboratories around the world.
 DE    Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PREVENTION &  CONTROL
       AIDS Serodiagnosis/*STANDARDS  AIDS Vaccines/*STANDARDS  Enzyme-Linked
       Immunosorbent Assay  Human  *HIV-1/IMMUNOLOGY/ISOLATION & PURIF
       Leukocytes, Mononuclear/MICROBIOLOGY  Neutralization Tests  Reference
       Standards  T-Lymphocytes/MICROBIOLOGY  MEETING REPORT  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).